Hershlag A, Napolitano B, Cangemi C, Scholl G, Rosenfeld D
Department of Obstetrics and Gynecology, North Shore University Hospital, Manhasset, New York 11030.
Fertil Steril. 1994 May;61(5):867-71. doi: 10.1016/s0015-0282(16)56698-9.
To determine the effect of antisperm antibodies in the female serum on fertilization and pregnancy rates (PRs) in assisted reproductive technology (ART) cycles.
Retrospective case control study.
Assisted reproductive technology program at North Shore University Hospital.
PATIENTS, PARTICIPANTS: All patients undergoing an ART cycle in 1990 whose husbands did not have significant antisperm antibodies in the semen. Thirty-four female patients had significant antisperm antibodies level in the serum (antisperm antibodies-significant); 62 patients with no antibodies or nonsignificant levels constituted the control group (antisperm antibodies-negative). Incubation media were prepared with maternal serum in 37 of the antisperm antibodies-negative and in 10 of the antisperm antibodies-positive patients, whereas donor's serum (DS) was used for 25 and 24 patients, respectively.
Fertilization rate and clinical PR, defined as an intrauterine sac by transvaginal ultrasonography, were recorded for each group.
Analysis of variance showed a significant interaction between antisperm antibodies grouping and the type of media used, with fertilization rate in antisperm antibodies-significant patients significantly higher with maternal serum than with DS, whereas fertilization rate in antisperm antibodies-negative was quantitatively, though not statistically lower with maternal serum than with DS. When maternal serum was used, fertilization was higher in antisperm antibodies-significant than antisperm antibodies-negative. Of 29 clinical pregnancies, 11 were in antisperm antibodies-significant and 18 in antisperm antibodies-negative. In 10 of the pregnancies, maternal serum was used, whereas in 19 pregnancies DS was used. No variable was significantly predictive of pregnancy in the logistic regression analysis.
[1] Female patients with significant levels of antisperm antibodies in the serum had similar fertilization rates as patients with nonsignificant levels if DS was used. [2] The use of maternal serum in antisperm antibodies-significant patients did not result in inferior fertilization rates or the occurrence of pregnancy. [3] These findings suggest that a female antisperm antibodies may not hinder fertilization in vitro. [4] This study questions the value of routine screening of female serum for antisperm antibodies in ART.
确定女性血清中的抗精子抗体对辅助生殖技术(ART)周期中受精率和妊娠率(PRs)的影响。
回顾性病例对照研究。
北岸大学医院辅助生殖技术项目。
患者、参与者:1990年所有接受ART周期治疗且其丈夫精液中无显著抗精子抗体的患者。34名女性患者血清中抗精子抗体水平显著(抗精子抗体-显著组);62名无抗体或抗体水平不显著的患者构成对照组(抗精子抗体-阴性组)。在抗精子抗体-阴性组的37名患者和抗精子抗体-阳性组的10名患者中,使用母体血清制备培养介质,而分别有25名和24名患者使用供体血清(DS)。
记录每组的受精率和临床妊娠率,临床妊娠率定义为经阴道超声检查发现宫内孕囊。
方差分析显示抗精子抗体分组与所用培养基类型之间存在显著交互作用,抗精子抗体-显著组患者使用母体血清时的受精率显著高于使用DS时,而抗精子抗体-阴性组使用母体血清时的受精率在数量上虽低于使用DS时,但无统计学差异。当使用母体血清时,抗精子抗体-显著组的受精率高于抗精子抗体-阴性组。29例临床妊娠中,11例在抗精子抗体-显著组,18例在抗精子抗体-阴性组。其中10例妊娠使用母体血清,19例妊娠使用DS。逻辑回归分析中无变量能显著预测妊娠。
[1] 如果使用DS,血清中抗精子抗体水平显著的女性患者受精率与抗体水平不显著的患者相似。[2] 在抗精子抗体-显著组患者中使用母体血清不会导致受精率降低或妊娠发生。[3] 这些发现表明女性抗精子抗体可能不会阻碍体外受精。[4] 本研究质疑在ART中常规筛查女性血清抗精子抗体的价值。